Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statin adverse event?

This article was originally published in The Tan Sheet

Executive Summary

Bayer withdraws Rx cholesterol-lowering statin Baycol (cerivastatin) due to prevalence of rhabdomyolysis, including 31 fatal cases, at low doses, FDA says Aug. 8. Agency suggests Baycol users talk to doctors about switching to alternative statins, including Merck's Mevacor and BMS' Pravachol, both of which were subject to OTC switch consideration last summer (1"The Tan Sheet" July 17, 2000, pp. 3-6). Public Citizen plans to petition FDA to include "black box" warning on all Rx statins informing patients of serious adverse event risks, group says
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS092915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel